- $1.59m
- -$3.49m
- $9.44m
Brief: Curis Announces Pricing Of $5.6 Million Public Offering
Curis Inc expected to post a loss of $7.84 a share - Earnings Preview
Curis Inc expected to post a loss of $7.47 a share - Earnings Preview
Brief: Curis Doses First Five Patients In Takeaim Cll Study
NASDAQ RESUMED AT 09:05 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Curis Announces Eleven Active Clinical Sites In TakeAim CLL Study
Curis Q1 operating loss widens as expenses rise
Curis Inc Q4 revenue misses estimates
Advisory: Alert incorrectly tagged to Curis Inc withdrawn
Brief: Curis Announces Closing Of Private Placement Totaling Up To $80.8 Million In Gross Proceeds
Brief: Curis Announces Pricing Of Private Placement Totaling Up To $80.8 Million In Gross Proceeds
Advisory: Alert incorrectly tagged to Curis Inc withdrawn
Biotech firm Curis beats Q3 revenue estimates
Brief: Curis Reports Inducement Grants Under Nasdaq Listing Rule